Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2014

View Archived Issues

Nymox reports nerve sparing and sexual preservation data on NX-1207

Pfizer and Cellectis establish cancer immunotherapy collaboration

Kyowa Hakko Kirin to begin a phase I trial of KHK-6640 for Alzheimer's disease

Flexion reports pharmacokinetic results for FX-006 in knee osteoarthritis

First data presented for ZP-GG-72, a dual GLP-1/2 agonist

Biosimilar infliximab BOW-015 shows equivalence in phase III trial

ProMetic completes phase I trial of PBI-4050

Protalix BioTherapeutics initiates phase II study of PRX-112

Zalicus licenses sodium channel pain modulation program to AnaBios

MRC Technology sells melanocortin receptor program to Pfizer

Janssen enters into license agreement with Vertex for influenza A treatment

Ziarco secures grant from U.K.'s Technology Strategy Board to advance ZPL-389

Asmacure discloses topline results of phase I/IIa trial of ASM-024 dry powder inhaler

Global ALS/MND Day news: Compounds with surprising effects in experimental ALS

Novel agents for cancer disclosed by Agios Pharmaceuticals

Researchers at AbbVie disclose novel PDE10A inhibitors

Portuguese group divulges agents for tuberculosis

Novartis patents new monophosphate prodrugs for viral infections

Merck & Co. designs novel gamma-secretase inhibitors

AT-13148 well tolerated in ongoing first-in-human study

Novel Ga-68 PET bone-targeting agent tested in vivo, ex vivo and in metastatic bone cancer patients

Sumitomo Dainippon Pharma approved as new English trade name

FDA accepts Cubist's NDA for ceftolozane sulfate/tazobactam sodium

Intec Pharma reports animal safety data for the Accordion Pill for carbidopa/levodopa

Sorafenib approved in Japan for thyroid carcinoma

Shire rejects acquisition proposal from AbbVie

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...